Tiziana Life Sciences Chairman Increases Stake with Recent Share Purchase

Tiziana Life Sciences ( (TLSA) ) has shared an update.

On May 12, 2025, Tiziana Life Sciences announced that its Executive Chairman and Founder, Mr. Gabriele Cerrone, has purchased 15,000 common shares at $1.55 per share, increasing his total holding to 43,252,143 common shares, which constitutes 37.02% of the issued share capital. This move underscores the chairman’s confidence in the company’s strategic direction and its ongoing development of intranasal foralumab, which is currently undergoing clinical trials for non-active secondary progressive multiple sclerosis. The purchase may positively impact stakeholder perception and reinforce the company’s position in the biotechnology industry.

More about Tiziana Life Sciences

Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies using transformational drug delivery technologies. The company is pioneering an innovative nasal approach for immunotherapy, with its lead candidate being intranasal foralumab, a fully human anti-CD3 monoclonal antibody. This approach aims to improve efficacy and safety compared to traditional intravenous delivery, and the company holds patents for its technology with several applications pending.

Average Trading Volume: 763,293

Technical Sentiment Signal: Buy

Current Market Cap: $175M

Find detailed analytics on TLSA stock on TipRanks’ Stock Analysis page.